• Human iPSC Hepatobiliary Organoids: Study Insights

  2026-08-29

  Wu et al. established a three-stage method for generating three-dimensional hepatobiliary organoids from human induced pluripotent stem cells without exogenous cells or genetic manipulation. The resulting structures combined hepatocyte-like and biliary functions, providing a platform for studying liver development, drug metabolism, and liver disease modeling.

• CHK1 Inhibition in ER/PR-Stratified Breast Cancer

  2026-08-28

  The reference study demonstrates that CHK1 inhibition has subtype-dependent effects in breast cancer: it enhances adriamycin sensitivity in ER−/PR−/HER2− disease but shows single-agent activity rather than chemosensitization in ER+/PR+/HER2− models. Its integrated database, drug-response, cell-cycle, apoptosis, and transcriptome analyses provide a framework for matching CHK1-targeted strategies to receptor status.

• α-Eudesmol Limits Ischemic Brain Injury via Cav2.1

  2026-08-28

  The reference study shows that α-eudesmol, an inhibitor of ω-agatoxin IVA-sensitive calcium channels, suppresses calcium-dependent glutamate release and reduces edema and infarction after focal cerebral ischemia in rats. Its value lies in connecting presynaptic P/Q-type channel pharmacology with acute ischemic neuroprotection, while also highlighting the selectivity limits of a small-molecule blocker.

• Decitabine Workflows for Cancer Epigenetics

  2026-08-27

  Decitabine enables controlled studies of DNMT1 inhibition, DNA hypomethylation, and tumor suppressor gene reactivation across hematologic and solid-tumor models. This workflow pairs dose–time design with molecular, phenotypic, and toxicity readouts so researchers can distinguish epigenetic priming from nonspecific cytotoxicity.

• In Situ TIL Therapy with Membrane-Anchored Anti-CD3

  2026-08-27

  The ACS Nano study introduces an in situ tumor-infiltrating lymphocyte strategy in which lipid nanoparticles deliver mRNA encoding a membrane-anchored anti-CD3 single-chain variable fragment to tumor-associated macrophages and tumor cells. This design combines local polyclonal T-cell activation with tumor-cell engagement and produces antitumor activity in B16F10 and MC38 models, including improved responses when paired with anti-PD-1 therapy.

• Ziprasidone Targets GOT1 in Pancreatic Cancer

  2026-08-26

  A 2022 Journal of Molecular Medicine study identified ziprasidone as a noncompetitive GOT1 inhibitor that disrupts glutamine metabolism, redox balance, and pancreatic ductal adenocarcinoma growth. Its combination of biochemical, cellular, genetic, metabolomic, and xenograft evidence supports GOT1 as a tractable metabolic target while leaving questions about selectivity and clinical translation unresolved.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-08-26

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult DNA templates. It is suited to blunt-ended products for cloning and sequencing, but not to workflows that require 3′-A overhangs or sticky ends.

• HBsAg Targets TBK1 to Evade Innate Immunity

  2026-08-26

  This 2025 Cell Death and Disease study identifies a direct mechanism by which hepatitis B surface antigen redirects TBK1 signaling away from IRF3-dependent type I interferon production and toward incomplete autophagy. The findings connect HBsAg-driven TBK1 dimerization, p62 phosphorylation, and SNAP29 suppression with HBV persistence, providing a mechanistic framework for studying viral immune evasion.

• Cy3 TSA Fluorescence System Kit for Spatial Biology

  2026-08-25

  Discover how the Cy3 TSA Fluorescence System Kit converts pathway-level cancer biology into high-sensitivity spatial evidence. This article links tyramide signal amplification to the miR-3180–SCD1–CD36 findings in hepatocellular carcinoma while clarifying controls, assay boundaries, and interpretation.

• SM-102 LNP Workflow for mRNA Delivery

  2026-08-24

  Build a more disciplined SM-102 lipid nanoparticle workflow with practical starting conditions, orthogonal quality checks, and troubleshooting logic. The approach combines bench screening with machine-learning insights while keeping claims tied to formulation context rather than assuming one ionizable lipid will outperform in every assay.

• MLN2238: Proteasome β5 Inhibition Workflows

  2026-08-24

  Build more informative proteasome-inhibition assays with MLN2238, combining nanomolar β5-site activity with pathway-level measurements of apoptosis, ROS, JNK, and CREB. Practical guidance covers solubility, dose selection, resistance models, and translation of Drosophila stress-response findings into mammalian workflows.

• Sulforaphane Workflows for Stress and Inflammation

  2026-08-23

  Translate Sulforaphane biology into reproducible cell, macrophage, and mouse workflows spanning oxidative stress, inflammasome signaling, and cancer chemoprevention. The article emphasizes dose selection, orthogonal readouts, and troubleshooting strategies that distinguish pathway modulation from nonspecific toxicity.

• GSK3 Inhibition Controls Mycobacterium tuberculosis

  2026-08-22

  The reference study identifies glycogen synthase kinase 3 as a host pathway that supports intracellular Mycobacterium tuberculosis growth and validates this target through pharmacological, CRISPR, RNAi, and phospho-proteomic approaches. Its findings strengthen the rationale for host-directed tuberculosis therapy, while also defining important mechanistic and translational limits for moving from macrophage models to treatment strategies.

• 2-NBDG Maps Glycolytic Uptake in Glioblastoma

  2026-08-21

  Learn how 2-NBDG can distinguish glucose transport and retention from downstream glycolytic activity in glioblastoma. This mechanistic guide connects fluorescent uptake measurements with recent PXDN–LDHA findings and practical assay design.

• JZL184 in Pain Research: Assay Design

  2026-08-20

  JZL184 is a selective monoacylglycerol lipase inhibitor for dissecting 2-AG biology, CB1 signaling, and pain-related behavior. This guide develops an assay-centered framework that connects endocannabinoid signaling modulation with sensory, affective, biochemical, and circuit-level readouts.

7880 records 1/526 page Next 12345 下5页 Last page